Kim J, Bradford D, Larkins E, Pai-Scherf LH, et al. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions. Clin Cancer Res 2021 May 27. pii: 1078-0432.CCR-21-0967.
PMID: 34045295